18,653 Shares in BioLife Solutions, Inc. (NASDAQ:BLFS) Bought by Alpha DNA Investment Management LLC

Alpha DNA Investment Management LLC purchased a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 18,653 shares of the medical equipment provider’s stock, valued at approximately $467,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. 1620 Investment Advisors Inc. acquired a new position in shares of BioLife Solutions in the 2nd quarter valued at $35,000. Isthmus Partners LLC boosted its stake in BioLife Solutions by 34.4% in the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 42,265 shares in the last quarter. Quest Partners LLC purchased a new position in shares of BioLife Solutions during the third quarter worth about $57,000. GAMMA Investing LLC grew its holdings in shares of BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 748 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of BioLife Solutions during the second quarter worth about $122,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, CRO Garrie Richardson sold 3,070 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $25.12, for a total transaction of $77,118.40. Following the completion of the transaction, the executive now directly owns 114,773 shares in the company, valued at approximately $2,883,097.76. This trade represents a 2.61 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Aby J. Mathew sold 17,604 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $20.05, for a total transaction of $352,960.20. Following the completion of the sale, the executive vice president now directly owns 284,442 shares in the company, valued at $5,703,062.10. This trade represents a 5.83 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 69,644 shares of company stock valued at $1,527,503. Corporate insiders own 2.20% of the company’s stock.

BioLife Solutions Trading Up 2.4 %

Shares of BioLife Solutions stock opened at $26.01 on Monday. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -24.54 and a beta of 1.88. BioLife Solutions, Inc. has a 52-week low of $11.91 and a 52-week high of $28.88. The company’s 50-day simple moving average is $24.00 and its 200-day simple moving average is $23.02.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on BLFS shares. HC Wainwright dropped their price target on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Craig Hallum increased their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. TD Cowen lifted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Northland Securities increased their price target on shares of BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, BioLife Solutions currently has an average rating of “Moderate Buy” and a consensus target price of $27.50.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.